SARS-CoV-2 Reinfection in a Liver Transplant Recipient

Ann Intern Med. 2021 Aug;174(8):1178-1180. doi: 10.7326/L21-0108. Epub 2021 Apr 20.

Authors

Christopher H Tomkins-Tinch¹, Jennifer S Daly², Adrianne Gladden-Young³, Nicole M Theodoropoulos², Michael P Madaio², Neng Yu², Vijay K Vanguri², Katherine J Siddle¹, Gordon Adams³, Lydia A Krasilnikova¹, Babak Movahedi², Adel Bozorgzadeh², Karl Simin², Jacob E Lemieux⁴, Jeremy Luban², Daniel J Park³, Bronwyn L MacInnis³, Pardis C Sabeti¹, Stuart M Levitz²

Affiliations

¹ The Broad Institute of MIT and Harvard and Harvard University, Cambridge, Massachusetts.
² University of Massachusetts Medical School, Worcester, Massachusetts.
³ The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
⁴ Massachusetts General Hospital, Boston, Massachusetts.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / diagnosis*
COVID-19 / virology
COVID-19 Nucleic Acid Testing
Humans
Immunocompromised Host*
Immunosuppressive Agents
Liver Transplantation*
Male
Middle Aged
Mycophenolic Acid / therapeutic use
Phylogeny
Reinfection*
SARS-CoV-2 / genetics
Tacrolimus / therapeutic use

Substances

Immunosuppressive Agents
Mycophenolic Acid
Tacrolimus

Grants and funding